Provided herein are methods for treating osteoporosis and increasing bone mass density, that includes administering once a day, for about 5 minutes, a transdermal patch loaded with about 300 μg of abaloparatide, and ZnCl.sub.2 at a molar ratio of 2.2:1 of ZnCl.sub.2:abaloparatide. Also provided are the single-use transdermal patches loaded with about 300 μg of abaloparatide, and ZnCl.sub.2 at a molar ratio of 2.2:1 of ZnCl.sub.2:abaloparatide.

Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

The present invention relates to a parathyroid hormone derivative in a dimeric form of a parathyroid hormone fragment and a pharmaceutical composition for the prevention or treatment of bone diseases comprising same. When administered to an animal model, the parathyroid hormone derivative in the dimeric form of the parathyroid hormone according to the present invention significantly increases bone density and enhances osteogenesis and thus can be effectively used for the treatment and prevention of bone diseases.

The present invention relates to a parathyroid hormone derivative in a dimeric form of a parathyroid hormone fragment and a pharmaceutical composition for the prevention or treatment of bone diseases comprising same. When administered to an animal model, the parathyroid hormone derivative in the dimeric form of the parathyroid hormone according to the present invention significantly increases bone density and enhances osteogenesis and thus can be effectively used for the treatment and prevention of bone diseases.

Provided herein are methods of enhancing spinal fusion and bone formation in subjects with spinal fractures, deformities or instability in the spine. The method includes administering (e.g., subcutaneously or transdermally) a therapeutically effective amount of abaloparatide to the subject.

Provided herein are methods of enhancing spinal fusion and bone formation in subjects with spinal fractures, deformities or instability in the spine. The method includes administering (e.g., subcutaneously or transdermally) a therapeutically effective amount of abaloparatide to the subject.

The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.

The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.